Benlysta (Belimumab) Market Size, Forecast, and Drug Insight - 2030 Benlysta (belimumab), developed by GlaxoSmithKline (GSK), is a monoclonal antibody specifically designed to target and inhibit B-lymphocyte stimulator (BLyS), a protein that plays a pivotal role in the survival of B cells. Approved for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis, Benlysta sales has marked a significant milestone in the management of autoimmune diseases by reducing disease activity and controlling flare-ups. For More : https://www.delveinsight.com/report-store/benlysta-belimumab-drug-insight-market-forecast